Appropriate aspirin use for primary prevention of cardiovascular disease
Miser, W.Fred.
American Family Physician 83(12): 1380-1386
2011
ISSN/ISBN: 0002-838X PMID: 21671538 Document Number: 652023
Document emailed within 1 workday
Related Documents
Selak, V.; Jackson, R.; Poppe, K.; Kerr, A.; Wells, S. 2018: Are the benefits of aspirin likely to exceed the risk of major bleeds among people in whom aspirin is recommended for the primary prevention of cardiovascular disease? New Zealand Medical Journal 131(1484): 19-25De Caterina, R. 2003: Low-dose aspirin in the primary prevention of cardiovascular disease: how to balance the benefits and the risks Italian Heart Journal: Official Journal of the Italian Federation of Cardiology 4(4): 228-231
Guo, Y.F. 2019: Effects of aspirin on primary prevention of cardiovascular events in patients with hypertension Zhonghua Nei Ke Za Zhi 58(4): 249-251
Maciá Bobes, C.; Ronzón Fernández, Aánzazu.; Fernández García, E. 2007: Primary prevention with aspirin for cardiovascular diseases in diabetic patients. What evidence supports the criteria of the ADA? Atencion Primaria 39(3): 163-164
Iavelov, I.S. 2006: Aspirin in primary prevention of cardiovascular events in women and men (a meta-analysis of randomized controlled trials) Kardiologiia 46(3): 75-76
Owens, D.K. 2017: Aspirin for the Prevention of Cardiovascular Disease and Colorectal Cancer: New Recommendations from the USPSTF American Family Physician 95(4): 222-223
De Caterina, R. 2001: The Primary Prevention Project Study Group. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice Italian Heart Journal. Supplement: Official Journal of the Italian Federation of Cardiology 2(6): 681-684
Lama, A.; Vega, Ján. 2004: Aspirin in the primary prevention of coronary disease. Is it good for everybody? Revista Medica de Chile 132(7): 886-888
Young, F.E.; Nightingale, S.L.; Temple, R.A. 1988: The preliminary report of the findings of the aspirin component of the ongoing Physicians' Health Study. The FDA perspective on aspirin for the primary prevention of myocardial infarction JAMA 259(21): 3158-3160
Garrett, R.E. 1986: Primary prevention of cardiovascular disease Journal of Family Practice 22(3): 222 224
Brohet, C. 1995: Risk factors and primary prevention of cardiovascular disease Journal de Pharmacie de Belgique 50(1): 20-24
García-Palmieri, M.R. 2000: Primary and secondary prevention of cardiovascular disease in the elderly Boletin de la Asociacion Medica de Puerto Rico 92(1-3): 3-8
Hiatt, W.R. 2008: Aspirin for prevention of cardiovascular events Bmj 337: A1806
Sobieszczańska, Młgorzata.; Kałka, D.; Pilecki, W.; Adamus, J. 2009: Physical activity in basic and primary prevention of cardiovascular disease Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego 26(156): 659-664
Fretheim, A.; Bjørndal, A.; Oxman, A.D.; Dyrdal, A.; Golding, M.; Ose, L.; Reikvam, A.; Teisberg, P. 2002: Which cholesterol-lowering drugs should be used in the primary prevention of cardiovascular disease? Tidsskrift for den Norske Laegeforening: Tidsskrift for Praktisk Medicin Ny Raekke 122(23): 2287-2288
Kulbertus, H. 2005: Aspirin and cardiovascular prevention: last minute information Revue Medicale de Liege 60(3): 198-200
Hovens, M.M.C.; Cannegieter, S.C. 2004: Acetylsalicylic acid in patients with diabetes for the primary prevention of cardiovascular disease Nederlands Tijdschrift Voor Geneeskunde 148(42): 2097; Author Reply 2097-8
Nordt, T. 2001: Primary prevention of cardiovascular events by ASS and vitamin E. PPP--Primary Prevention Project Der Internist 42(12): 1705-1707
Rus, H.; Niculescu, F.I. 1997: Inflammation, aspirin, and the risk of cardiovascular disease New England Journal of Medicine 337(6): 423; Author Reply 423-424
Burrill, P.D. 2010: Aspirin in primary prevention. Evidence is lacking Bmj 340: C1613